ArticleMedicine2026
Association of endometriosis with hematuria markers: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Identification of appropriate biomarkers is of great clinical significance for early diagnosis of endometriosis (EMs). This study aimed to comprehensively analyze the association between EMs and blood and urine biomarkers (BUB). Candidate EMs-related single nucleotide polymorphisms were obtained from recent genome-wide association studies. The UK Biobank cohort included 3,63,228 participants with BUB test data to calculate the polygenic risk score for EMs. Two-way, 2-sample Mendelian randomization (MR) was used to assess the potential relationship between candidate BUB and EMs. We found a significant association between EMs and triglycerides and calcium in both forward and reverse MR (r > 1, P < .05). In the positive MR analysis, we also found that insulin-like growth factor-1 was a risk factor for EMs, and high-density lipoprotein was a protective factor for EMs. Our findings provide insights into the role of BUB in the early detection and treatment of EMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.